A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
A phase 2 trial of SYS6023 and KN026 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.
Overview
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer is a phase 2 interventional study registered as NCT07597629 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 36 participants planned, started 2026-05-25 and due to reach its primary completion in 2027-11-30. Interventions recorded: SYS6023 and KN026.
Similar pages
not linked directly; found by shared links- TrialClinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.